Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-24 @ 12:37 PM
Ignite Modification Date:
2025-12-24 @ 12:37 PM
NCT ID:
NCT05046561
Brief Summary:
Protocol STRI12 - Study to Reinforce Immunity (STRI) - A Phase 2 Double-Blind, Randomized, Placebo-Controlled Study to Investigate the Safety and Efficacy of STRI Formula in Non-Hospitalized Participants with COVID-19 (the Study)
Detailed Description:
The Study to Reinforce Immunity (STRI) Phase 2 Clinical Trial is a randomized, double-blind, placebo-controlled clinical trial protocol assessing the safety and efficacy of STRI Formula in non-hospitalized participants with COVID-19. STRI Formula is a combination of food-based substances designed specifically to combat SARS-CoV-2, the coronavirus that causes COVID-19.
The primary objective of the Study is to assess the efficacy of STRI Formula in reduction of time from treatment initiation to initial meaningful clinical improvement in COVID-19 symptoms. Additional secondary objectives are as follows:
1. To assess the safety of STRI Formula
2. To assess the efficacy of STRI Formula in reduction of time to COVID-19 sustained symptom improvement
3. To assess the efficacy of STRI Formula in reduction of time to COVID-19 initial symptom resolution
4. To assess the efficacy of STRI Formula in reduction of time to COVID-19 sustained symptom resolution
5. To assess the efficacy of STRI Formula in reduction in need for hospitalization
6. To assess the efficacy of STRI Formula in reduction in rates of fever
7. To assess the efficacy of STRI Formula in reduction in rates of hypoxia
Study:
NCT05046561
Study Brief:
Protocol Section:
NCT05046561